Program and Abstracts from the Canadian Digestive Diseases Week 2016

Table 1

Clinical, Endoscopic, and Laboratory Features of 80 IBD Patients Undergoing Colonoscopy at the University of Alberta Inflammatory Bowel Disease Clinic.

	Crohn’s Disease	Ulcerative Colitis
(%)	40 (50.0)	40 (50.0)
Male (%)	17 (42.5)	15 (37.5)
Disease Extent (%)	—	—
Ileal	20 (50.0)	—
Ileocolonic	13 (32.5)	—
Colonic	7 (17.5)	—
Proctitis	—	3 (7.5)
Left-sided	—	13 (32.5)
Pancolitis	—	24 (60.0)
Active IBD Treatment (%)	—	—
Steroids	1 (2.5)	1 (2.5)
Biologics	15 (37.5)	8 (20.0)
Immunomodulators	15 (37.5)	14 (35.0)
Endoscopic MH	26 (65.0)	24 (60.0)
Biomarkers (median, IQR)	—	—
FCP (g/g)	330 (215–599)	322 (199–607)
FIT (ng/mL)	81 (15–1000)	421 (30–1000)
Sensitivity for MH	—	—
FCP < 150 g/g	1.00	0.94
FIT < 50 g/mL	0.57	0.81